ArticleCureus2025
The Need for Uniform Labeling Regulations for Monosodium Glutamate to Address Health Risks and Consumer Protection.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monosodium glutamate (MSG) is a flavor enhancer commonly added to processed foods. Despite its GRAS (Generally Recognized as Safe) status by the FDA, accumulating clinical evidence, in the form of multiple case reports, links MSG to serious health risks in susceptible individuals, particularly those prone to atrial fibrillation (AF). Biological mechanisms, including glutamate receptor activity and oxidative stress, are believed to be the cause of this adverse effect. Moreover, inconsistent labeling practices disguise MSG under multiple names, making it difficult for sensitive consumers to avoid. The European Union, Australia, and Japan enforce stricter MSG labeling requirements than the United States to safeguard the susceptible population. This paper makes the case for uniform labeling regulations to promote transparency and protect at-risk populations from inadvertent exposure to MSG, advocating for standardized ingredient disclosure policies modeled on international practices.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.